B. Riley Securities Reiterates Buy on Journey Medical, Raises Price Target to $15
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $12 to $15.
B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $12 to $15.